Trial Profile
A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Mosunetuzumab (Primary) ; Mosunetuzumab (Primary) ; Polatuzumab vedotin; Tocilizumab
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 12 Dec 2023 preliminary Results (at data cut off Feb 17, 2023, n=108) assessing safety and efficacy of Mosunetuzumab and Polatuzumab Vedotin in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 31 Aug 2023 Planned End Date changed from 20 Feb 2024 to 3 Aug 2025.
- 23 Feb 2023 The trial has been suspended in Spain, European Clinical Trials Database record.